Trial · NCT01127607
Results by group244
Each measurement the trial posted, group by group, in the words and numbers it posted.
221 to 240 of 244
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 50 mg Lisdexamfetamine | tearful, sad, depressed | 19.0 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 70 mg Lisdexamfetamine | tearful, sad, depressed | 11.8 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | No Medication | socially withdrawn | 5.3 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 30 mg Lisdexamfetamine | socially withdrawn | 8.3 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 50 mg Lisdexamfetamine | socially withdrawn | 0.0 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 70 mg Lisdexamfetamine | socially withdrawn | 0.0 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | No Medication | loss of appetite | 0.0 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 30 mg Lisdexamfetamine | loss of appetite | 52.8 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 50 mg Lisdexamfetamine | loss of appetite | 66.7 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 70 mg Lisdexamfetamine | loss of appetite | 70.6 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | No Medication | trouble sleeping | 10.5 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 30 mg Lisdexamfetamine | trouble sleeping | 30.6 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 50 mg Lisdexamfetamine | trouble sleeping | 33.3 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 70 mg Lisdexamfetamine | trouble sleeping | 35.3 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | No Medication | dry mouth | 0.0 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 30 mg Lisdexamfetamine | dry mouth | 30.6 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 50 mg Lisdexamfetamine | dry mouth | 38.1 | Percent of participants | |
| Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | 70 mg Lisdexamfetamine | dry mouth | 70.5 | Percent of participants | |
| Adult ADHD Rating Scale Completed at the End of the Med Optimization Phase | Unmedicated | Inattention Symptoms | 23.12 | Standard Deviation 3.58 | scores on a scale |
| Adult ADHD Rating Scale Completed at the End of the Med Optimization Phase | Optimal Dose of Medication | Inattention Symptoms | 9.77 | Standard Deviation 4.44 | scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01127607/results?page=12